TScan Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

Rhea-AI Summary

TScan Therapeutics, Inc. (Nasdaq: TCRX), a company focused on T cell receptor (TCR) engineered therapies for cancer, will have its CEO, David P. Southwell, participate in a virtual panel at the 13th Annual Wedbush PacGrow Healthcare Conference on August 10, 2022, at 1:10 p.m. ET. This discussion titled “A View to a Kill(er Cell)” will delve into advancements in TCR-T therapies. A webcast of the panel will be available on TScan's website, along with an archived replay for 30 days after the event.

The company is developing TCR-T therapies aimed at hematologic malignancies and solid tumors.

WALTHAM, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that David P. Southwell, President and Chief Executive Officer, will participate in a virtual panel discussion titled “A View to a Kill(er Cell)” at the 13^th Annual Wedbush PacGrow Healthcare Conference on Wednesday, August 10, 2022 at 1:10 p.m. ET.

A webcast of the panel discussion will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 30 days following the event.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after hematopoietic stem cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types in order to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.

Contacts:

Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com

Joyce Allaire
LifeSci Advisors, LLC
Managing Director
617-435-6602
jallaire@lifesciadvisors.com

 

FAQ

What is TScan Therapeutics' stock symbol?

TScan Therapeutics trades under the stock symbol TCRX.

When is TScan Therapeutics participating in the Wedbush PacGrow Healthcare Conference?

TScan Therapeutics will participate in the conference on August 10, 2022.

Who from TScan Therapeutics will speak at the conference?

David P. Southwell, the President and CEO, will participate in the panel discussion.

What is the topic of the panel discussion by TScan Therapeutics?

The panel discussion is titled 'A View to a Kill(er Cell)'.

Where can I watch the TScan Therapeutics panel discussion?

The panel discussion can be viewed on TScan's website under the Events and Presentations section.

How long will the panel webcast be available after the event?

The archived replay of the webcast will be available for 30 days following the event.